article
USA and Japan based privately held company Aurion Biotech announced that the US Food and Drug Administration (FDA) has granted both Breakthrough Therapy designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) designation for AURN001, the company’s allogeneic cell therapy candidate for the treatment of corneal edema secondary to corneal endothelial disease. 20 June 2024